Member Info for ontarget

Very interesting interview with Gregory Bailey from Juvenescence, dated yesterday:

https://vimeo.com/556541905/fa8f27c9a8

8:50-10:10 talks about their (Evgen's) Sulforaphane supplement

17:00 onwards talks about pricing/volumes - big bucks!

Nice. Just 50k available now at 8.8 without going NT.

Misleading RNS's as it doesn't show the previous holdings (maybe doesn't need to as they were pre-listing and so never declared through TR-1).
These RNS's are just showing their massive reduction in % held thanks to the recent 1.5p placing - the number of shares held hasn't changed.

Also 'during' doesn't mean at the end, so we could well hear something before the end of May (although not looking likely as only today and Friday left as trading days!)

Out of interest, where did you hear end of May, Phil?

At least since about 2 days ago it's now trading fairly normally, moving up on buys and down on sells, instead of the interminable invisible seller we've had to put up with for the last 6 months or more.

Same reason as always, they are above mid-price.

If the interim efficacy assessment finds SFX-01 has efficacy the trial will be halted (and proceed to the next stage) I believe, because it would be morally wrong to proceed with giving 50% of patients the placebo instead of the effective drug.

Someone's trying to buy 200k on level 2 - was at 102 now moved up to 104.

Just wait for the US to open.

Online offer has completely dried up the morning. I also have the feeling we cleared something out that was holding us back yesterday. Also FCAP widened their spread and not on either bid or offer.

That was at 16:24, not after market close - just to clarify.

FCAP have now moved off the 7.22 offer onto the bid with a 7.6 offer.
So hopefully that's the 7.2 stock taken out?!

Offering 7.2 now.

The all-time low was 2.875p, but certainly around the low for the last year.
Can't be much longer now as it's been at least 7 weeks since the 100th patient should have completed.

.

Bottom line is Pharmagra gets 10% of any revenues from licencing deals and a 3.5% royalty on Evgen's own net sales.
In other words if we make lots of money, we have to give a bit of it to Pharmagra. If we don't make any money we don't give them anything.

You can fins more info in the admission document mrshoubs:
https://evgen.com/wp-content/uploads/2015/10/FINAL-Evgen-Pharma-plc-AIM-Admission-Document.pdf

Would be nice if the likes of Octopus, RAB etc. would like a little top-up on top of their 8p placing shares, but I guess they're waiting for the efficacy results now in case they can get some a few p cheaper?

$26m mcap

https://money.tmx.com/en/quote/ASND